The Zacks Analyst Blog Highlights:Verizon Communications, Sanofi,
Novo-Nordisk, Johnson & Johnson and Roche
CHICAGO, Dec. 14, 2012
CHICAGO, Dec. 14, 2012 /PRNewswire/ --Zacks.com announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include Verizon Communications Inc.
(NYSE:VZ), Sanofi (NYSE:SNY), Novo-Nordisk (NYSE:NVO), Johnson & Johnson
(NYSE:JNJ) and Roche (OTC:RHHBY).
Get the most recent insight from Zacks Equity Research with the free Profit
from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Thursday's Analyst Blog:
Verizon Expands 100G Technology
Verizon Communications Inc. (NYSE:VZ) seems to be on an expansion spree as it
has extended its 100G network in the U.S. and Europe besides deploying 4G LTE
network in several U.S. markets. The rapidly growing telecom traffic demand is
forcing the company to expand its network infrastructure. The largest telecom
operator in the U.S. has expanded by a massive 20,921 kilometers in the U.S.
and by 2,600 kilometers in Europe.
In the U.S., Verizon has deployed its 100G technology in some select markets
like Atlanta-Tampa, Kansas-Dallas and Salt Lake City-Seattle, where data
demand is the highest. Alongside, within Europe, the company expanded its 100G
technology in two new routes including the lucrative London-Paris and
100G or 100 Gigabyte Ethernet is a high speed computer network standard that
supports data transfer at a speed of 100GB per second, which is 10 times
better than the previous fastest Ethernet standard with a speed of 10GB per
second. 100G technology supports both fixed and wireless services to create a
high capacity network, which allows super-fast data transfer in multiple
In November, 2007, Verizon became the first operator in the U.S. to
successfully complete the trial of 100G technology. Several trials followed
and in March 2011, the company deployed the 100G network in Europe, thereby
expanding the infrastructure and performance for its customers. Following the
European launch, Verizon successfully launched the network technology in
several U.S. markets.
Sanofi Presents Positive Results
Sanofi (NYSE:SNY) recently announced positive results from a phase II trial
evaluating the efficacy of its hematology candidate, SAR302503 (selective JAK2
inhibitor) in three dose strengths (300 mg, 400 mg, and 500 mg) for the
reduction of spleen volume and improvement in constitutional symptoms in
intermediate-2 or high-risk primary or secondary myelofibrosis (MF) patients.
The data was presented at the American Society of Hematology's (ASH) annual
The open label, randomized dose-ranging phase II trial evaluated SAR302503 in
31 patients. The candidate met the primary endpoint of reducing spleen volume.
Currently, the phase III JAKARTA trial, evaluating the use of SAR302503 in 289
patients, is underway. Initial data from the trial should be out by the second
quarter of 2013. Two dose strengths (400 mg and 500 mg) of SAR302503 are being
studied in the JAKARTA trial.
We are pleased with Sanofi's progress with its pipeline. Over the last few
months, several of Sanofi's pipeline candidates gained approval including US
approval of Aubagio (teriflunomide) for relapsing forms of multiple sclerosis
(RMS) and US approval of Zaltrap (aflibercept) as a combination therapy for
treatment-experienced patients suffering from metastatic colorectal cancer.
We expect Sanofi to continue to contain operating costs in order to increase
earnings in the face of weakening sales of some of its biggest products. We
also expect the company to pursue bolt-on acquisitions.
Currently, we have a Neutral recommendation on Sanofi. Sanofi carries a Zacks
#2 Rank (Buy) in the short run.
Large-cap pharma stocks currently holding a Zacks #2 Rank include companies
like Novo-Nordisk (NYSE:NVO), Johnson & Johnson (NYSE:JNJ) and Roche
Want more from Zacks Equity Research? Subscribe to the free Profit from the
Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the
Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment Research is through our free daily email
newsletter; Profit from the Pros. In short, it's your steady flow of
Profitable ideas GUARANTEED to be worth your time! Register for your free
subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance
numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook:
Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
Zacks Investment Research
800-767-3771 ext. 9339
SOURCE Zacks Investment Research, Inc.
Press spacebar to pause and continue. Press esc to stop.